Catlin Avery W

AVANT Immunotherapeutics, Inc.

Sr. VP & CFO

Avg. Two Year Performance

118% Avg. Purchase Return 48% Compound

42% Avg. Sale Return 19% Compound

Holdings: 83.59K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Diagnostic Substances

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions